Boehringer Ingelheim flies the white flag as last holdout surrenders in war over a $20B AbbVie gold mine
After battling it out in the courts as the last big holdout in the fight over AbbVie’s Humira patents, Boehringer Ingelheim has dropped neatly …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
